3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Ovarian Neoplasms
39
Breast Neoplasms
24
Neoplasms
12
Prostatic Neoplasms
11
Triple Negative Breast Neoplasms
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Pancreatic Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Ovarian Epithelial
6
Stomach Neoplasms
5
Metastatic Castration-resistant Prostate Cancer
5
Fanconi Anemia, Complementation Group D1
5
Small Cell Lung Carcinoma
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Solid Tumors
4
Solid Tumors
3
Fallopian Tube Neoplasms
3
Endometrial Neoplasms
3
Prostatic Neoplasms, Castration-Resistant
2
Colorectal Neoplasms
2
Carcinoma
2
Advanced Solid Tumours
2
Advanced Solid Tumor
2
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Diseases
1
Platinum-sensitive Ovarian Cancer
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Interventions
Paclitaxel
2
Carboplatin
2
zenocutuzumab
1
pertuzumab
1
pemigatinib
1
olaparib
1
ivosidenib
1
ipatasertib
1
entrectinib
1
cobimetinib
1
belinostat
1
atezolizumab
1
alectinib
1
Vemurafenib
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Mebendazole
1
Immunotherapy
1
HhAntag691
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Drug Therapy
1
Cisplatin
1
CP protocol
1
Biological Therapy
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms, Unknown Primary
×
olaparib
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts